Go Pro
LON:DOCS

Dr. Martens (DOCS) Share Price, News & Analysis

Dr. Martens logo
GBX 79.74 +0.34 (+0.43%)
As of 08/5/2026 12:18 PM Eastern

About Dr. Martens Stock (LON:DOCS)

Advanced

Key Stats

Today's Range
78.90
81.06
50-Day Range
69.11
79.74
52-Week Range
59.15
100.87
Volume
53.85 million shs
Average Volume
7.96 million shs
Market Capitalization
£763.22 million
P/E Ratio
33.23
Dividend Yield
3.28%
Price Target
GBX 105
Consensus Rating
Moderate Buy

Company Overview

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over 60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the 1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and accessories. The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and is a constituent of the FTSE 250 index. Dr. Martens operates across three geographic regions: EMEA, Americas and APAC. Our product segments include Originals, Fusion, Kids and Casual and a complementary range of Accessories.

Dr. Martens Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
81st Percentile Overall Score

DOCS MarketRank™: 

Dr. Martens scored higher than 81% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Dr. Martens has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and no sell ratings.

  • Upside Potential

    Dr. Martens has a consensus price target of GBX 105, representing about 31.7% upside from its current price of GBX 79.74.

  • Amount of Analyst Coverage

    Dr. Martens has only been the subject of 2 research reports in the past 90 days.

  • Read more about Dr. Martens' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Dr. Martens is 33.23, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 46.21.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Dr. Martens is 33.23, which means that it is trading at a less expensive P/E ratio than the Consumer Discretionary sector average P/E ratio of about 47.85.

  • Price to Earnings Growth Ratio

    Dr. Martens has a PEG Ratio of 6.40. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Dr. Martens has a P/B Ratio of 2.11. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for DOCS.
  • Dividend Yield

    Dr. Martens pays a meaningful dividend of 3.28%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Dr. Martens does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Dr. Martens is 106.25%. Payout ratios above 75% are not desirable because they may not be sustainable.

  • Read more about Dr. Martens' dividend.
  • News Sentiment

    Dr. Martens has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.64 average news sentiment score of Consumer Discretionary companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Dr. Martens this week, compared to 2 articles on an average week.
  • Search Interest

    Only 5 people have searched for DOCS on MarketBeat in the last 30 days. This is a decrease of -58% compared to the previous 30 days.
  • Cluster Insider Buying

    2 insiders have purchased shares of Dr. Martens in the last three months. Multiple insiders buying is a strong bullish signal.

  • Net Insider Buying

    Over the last three months, insiders have purchased a net £220,614.08 in company stock, which represents 0.0289% of the company's market cap.

  • Insider Buying vs. Insider Selling

    In the past three months, Dr. Martens insiders have bought more of their company's stock than they have sold. Specifically, they have bought £220,614.08 in company stock and sold GBX 0 in company stock.

  • Percentage Held by Insiders

    2.94% of the stock of Dr. Martens is held by insiders.

  • Percentage Held by Institutions

    19.06% of the stock of Dr. Martens is held by institutions.

  • Read more about Dr. Martens' insider trading history.
Receive DOCS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dr. Martens and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

DOCS Stock News Headlines

Dr. Martens Adds New Shares Under Employee Schemes on LSE
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now.tc pixel
See More Headlines

DOCS Stock Analysis - Frequently Asked Questions

Dr. Martens' stock was trading at GBX 76.60 at the start of the year. Since then, DOCS stock has increased by 4.1% and is now trading at GBX 79.74.

Dr. Martens plc (LON:DOCS) released its quarterly earnings results on Tuesday, May, 19th. The company reported $4.20 earnings per share (EPS) for the quarter. The company earned $764.90 million during the quarter. Dr. Martens had a net margin of 3.11% and a trailing twelve-month return on equity of 6.89%.
Read the conference call transcript
.

Shares of DOCS stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Based on aggregate information from My MarketBeat watchlists, some other companies that Dr. Martens investors own include boohoo group (BOO), Aston Martin Lagonda Global (AML), ASOS (ASC), Vodafone Group Public (VOD), JD Sports Fashion (JD), Legal & General Group (LGEN) and Lloyds Banking Group (LLOY).

Company Calendar

Last Earnings
5/19/2026
Today
8/05/2026

Industry, Sector and Symbol

Stock Exchange
LON
Industry
Textiles, Apparel & Luxury Goods
Sub-Industry
N/A
Current Symbol
LON:DOCS
CIK
N/A
Fax
N/A
Employees
890
Year Founded
N/A

Price Target and Rating

High Price Target
GBX 110
Low Price Target
GBX 100
Potential Upside/Downside
+31.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
GBX 2.40
Trailing P/E Ratio
33.23
Forward P/E Ratio
30.90
P/E Growth
6.4
Net Income
£68.97 million
Net Margins
3.11%
Pretax Margin
N/A
Return on Equity
6.89%
Return on Assets
8.12%

Debt

Debt-to-Equity Ratio
108.85
Current Ratio
2.61
Quick Ratio
1.13

Sales & Book Value

Annual Sales
£764.90 million
Price / Sales
1.00
Cash Flow
GBX 5.58 per share
Price / Cash Flow
14.29
Book Value
GBX 37.80 per share
Price / Book
2.11

Miscellaneous

Outstanding Shares
957,113,000
Free Float
N/A
Market Cap
£763.22 million
Optionable
Not Optionable
Beta
0.25
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

This page (LON:DOCS) was last updated on 8/6/2026 by MarketBeat.com Staff.
From Our Partners